Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Prignano

Showing results (181-190 of 194) with videos related to

Pageof 20
Sort By:
Plos One|August 14, 2020
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasisEmanuele Scala, Matteo Megna, Paolo Amerio, et al.
The Journal of Dermatological Treatment|February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER studyClaudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 11, 2024
Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort studyAndrea Chiricozzi, Giulia Coscarella, Luis Puig, et al.
Dermatology and Therapy|January 11, 2021
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus RecommendationsPaolo Gisondi, Marina Talamonti, Andrea Chiricozzi, et al.
Clinical Rheumatology|November 6, 2020
Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP studyEnnio Lubrano, Andrea Delle Sedie, Marco Romanelli, et al.
Clinical, Cosmetic and Investigational Dermatology|December 18, 2023
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 StudyFilomena Russo, Marco Galluzzo, Luca Stingeni, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2025
Switching to brodalumab after failure of IL-17A inhibitors in psoriatic patients: A real-life multicentre studyRiccardo Balestri, Giulia Odorici, Michela Magnano, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 13, 2025
Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologicsGeorgios Nikolakis, Erkan Alpsoy, Monika Arenbergerova, et al.
Pharmaceuticals (Basel, Switzerland)|October 26, 2024
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life StudyElena Campione, Fabio Artosi, Ruslana Gaeta Shumak, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 24, 2026
Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativaGeorgios Nikolakis, Erkan Alpsoy, Florian Anzengruber, et al.
Pageof 20

Showing results (181-190 of 194) with videos related to

Sort By:
Pageof 20
Plos One|August 14, 2020
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasisEmanuele Scala, Matteo Megna, Paolo Amerio, et al.
The Journal of Dermatological Treatment|February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER studyClaudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 11, 2024
Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort studyAndrea Chiricozzi, Giulia Coscarella, Luis Puig, et al.
Dermatology and Therapy|January 11, 2021
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus RecommendationsPaolo Gisondi, Marina Talamonti, Andrea Chiricozzi, et al.
Clinical Rheumatology|November 6, 2020
Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP studyEnnio Lubrano, Andrea Delle Sedie, Marco Romanelli, et al.
Clinical, Cosmetic and Investigational Dermatology|December 18, 2023
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 StudyFilomena Russo, Marco Galluzzo, Luca Stingeni, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2025
Switching to brodalumab after failure of IL-17A inhibitors in psoriatic patients: A real-life multicentre studyRiccardo Balestri, Giulia Odorici, Michela Magnano, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 13, 2025
Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologicsGeorgios Nikolakis, Erkan Alpsoy, Monika Arenbergerova, et al.
Pharmaceuticals (Basel, Switzerland)|October 26, 2024
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life StudyElena Campione, Fabio Artosi, Ruslana Gaeta Shumak, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 24, 2026
Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativaGeorgios Nikolakis, Erkan Alpsoy, Florian Anzengruber, et al.
Pageof 20